ALEC at a glance
Alector, Inc. (ALEC, SEC CIK 1653087) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as September 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Alector, Inc. (ALEC) reported revenue of $21.0 million (down 79.1% from FY2024) and a net loss of $142.9 million. Diluted EPS was -$1.39.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Alector, Inc. (ALEC) shares worth $65.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Wong-Sarad Grace on September 4, 2026 of 3,625 shares at $2.51 per share.
- In the last 90 days, ALEC insiders reported 0 open-market purchases ($0) and 5 open-market sales ($296K) on Form 4, a net sale of $296K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $21.0M
- −79.1% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$296K
- 13F holders
- 27 funds
- $65.8M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Collaboration revenue $3.3M, down $4.6M from $7.9M YoY, primarily lower AL101 AD revenue
- Net loss $23.0M vs $30.5M YoY; operating loss $24.4M vs $34.1M
- AL037/AL137 highest R&D spending at $5.0M; nivisnebart lowest at $0.7M
- Cash, equivalents and securities $172.8M; operating cash used $84.0M versus $109.8M YoY
- Runway at least through 2027; GSK termination effective January 2, 2027, with additional funding needed
Risk Factors
- Newly triggered development setback: GSK discontinued nivisnebart’s Phase 2 PROGRESS-AD trial in April 2026 after interim futility analysis
- Most material pipeline change: no active clinical trials after latozinemab, nivisnebart, and AL002 discontinuations
- Regulatory risk: FDA or other agency staffing and funding changes could delay product development or commercialization
- Near-term operational risk: preclinical-only pipeline leaves success dependent on advancing unproven neurodegenerative programs
- Liquidity risk: $172.8 million in cash, equivalents, and marketable securities projected to fund operations at least through 2027
AI summary of the ALEC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results cover the quarter ended June 30, 2026
- Earnings press release furnished as Exhibit 99.1, containing the detailed financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $3.3M, down from $7.9M, reflecting lower AL101 AD collaboration revenue
- Net loss narrowed to $23.0M, or $0.21 per share, from $30.5M, or $0.30
Item 1.02: Termination of a Material Definitive Agreement
- GSK termination follows failed Phase 3 latozinemab and discontinued Phase 2 nivisnebart programs
- Collaboration ends January 2, 2027, removing GSK partnership support for both progranulin-antibody programs
AI summaries of ALEC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALEC
Don't miss the next ALEC filing
- Alerts as it files. A push when ALEC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALEC, by share count.
- Ask anything. An AI agent that reads every ALEC filing and answers with sources.
ALEC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wong-Sarad Grace | Sell | Sep 4, 2026 | 3,625 | $2.51 |
| Berkley Neil Lindsay | Sell | Sep 3, 2026 | 29,251 | $2.66 |
| Wong-Sarad Grace | Sell | Sep 3, 2026 | 5,165 | $2.67 |
| Rosenthal Arnon | Sell | Sep 3, 2026 | 72,606 | $2.66 |
| Wong-Sarad Grace | Sell | Sep 2, 2026 | 656 | $2.75 |
| Rosenthal Arnon | G | Aug 19, 2026 | 350,000 | - |
| Rosenthal Arnon | G | Aug 19, 2026 | 1,050,000 | - |
| Rosenthal Arnon | G | Aug 19, 2026 | 350,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $100.6M | $21.0M |
| Operating Income | -$151.7M | -$145.0M | -$156.0M |
| Net Income | -$130.4M | -$119.0M | -$142.9M |
| Op. Margin | - | -144.2% | -741.3% |
| Net Margin | - | -118.4% | -679.2% |
| Balance Sheet | |||
| Total Assets | - | $468.3M | $293.2M |
| Equity | - | $126.8M | $30.6M |
| ROE | - | -93.9% | -466.3% |
| Per Share | |||
| EPS | $-1.56 | $-1.23 | $-1.39 |
| Cash Flow | |||
| Operating CF | - | -$229.9M | -$184.0M |
| CapEx | $2.4M | $1.3M | $41K |
Source: XBRL data in Alector, Inc. (ALEC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ALEC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $65.8M |
| Q1 2026 | 27 | $71.4M |
| Q4 2025 | 25 | $49.2M |
| Q3 2025 | 27 | $129.6M |
| Q2 2025 | 29 | $64.0M |
| Q1 2025 | 25 | $41.0M |
| Q4 2024 | 21 | $59.8M |
| Q3 2024 | 19 | $33.8M |
- AQR Capital Management+598.2K (+84%)
- Vanguard Capital Management LLC+330.6K (+9%)
- Citadel Advisors LLC+313.7K (+405%)
- Vanguard Portfolio Management LLC+237.0K (+9%)
- BlackRock+106.6K (+1%)
- FMR LLC (Fidelity)−399.7K (-22%)
- D.E. Shaw & Co−372.9K (-11%)
- Renaissance Technologies LLC−352.5K (-27%)
- Dimensional Fund Advisors−250.1K (-88%)
- Morgan Stanley−244.1K (-67%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 200 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALEC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| SC 13G | Sep 18, 2026 | - | - | |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 9, 2026 | - | - | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 17, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ACLX · Arcellx, Inc.Biological Products, (No Diagnostic Substances)
ALEC SEC filings: frequently asked questions
Are ALEC insiders buying or selling?
In the last 90 days, Alector, Inc. (ALEC) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $296,087 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALEC stock?
As of June 30, 2026, the largest Alector, Inc. (ALEC) holders among the 13F filers tracked by SignalX were BlackRock ($15.8 million), Vanguard Capital Management LLC ($8.1 million), Merck & Co. ($7.1 million), D.E. Shaw & Co ($6.0 million), Vanguard Portfolio Management LLC ($5.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALEC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Alector, Inc. (ALEC) reported revenue of $21.0 million (down 79.1% from FY2024) and a net loss of $142.9 million. Diluted EPS was -$1.39. The figures come from the XBRL data in the 10-K.
What did ALEC report in its latest 8-K?
Alector, Inc. (ALEC) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results cover the quarter ended June 30, 2026.
What are the latest ALEC SEC filings?
Alector, Inc. (ALEC) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on September 4, 2026.
What is ALEC's SEC CIK number?
Alector, Inc. (ALEC)'s SEC Central Index Key (CIK) is 1653087. EDGAR lists every ALEC filing under that number.
Ask anything about ALEC
The research agent reads ALEC's filings, financials, insider trades and 13F holders, then answers with sources.